Experienced in Progressive Familial Intrahepatic Cholestasis Type 3

Dr. Natarajan Ravendhran

Hepatology
Johns Hopkins University
600 N Wolf St, 
Baltimore, MD 
Experienced in Progressive Familial Intrahepatic Cholestasis Type 3
Johns Hopkins University
600 N Wolf St, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Natarajan Ravendhran is a Hepatologist in Baltimore, Maryland. Dr. Ravendhran is rated as an Experienced provider by MediFind in the treatment of Progressive Familial Intrahepatic Cholestasis Type 3. His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Hepatitis, Cirrhosis, Visceromegaly, and Endoscopy.

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hepatology
Licenses
Internal Medicine in MD
Hospital Affiliations
The Johns Hopkins Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

JOHNS HOPKINS UNIVERSITY
600 N Wolf St, Baltimore, MD 21287

Additional Areas of Focus

Dr. Ravendhran has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
View 6 Less Clinical Trials

22 Total Publications

Association of Carbohydrate Antigen 19-9 Elevation Among Patients With Alcohol-Related Liver Disease Undergoing Liver Transplant.
Association of Carbohydrate Antigen 19-9 Elevation Among Patients With Alcohol-Related Liver Disease Undergoing Liver Transplant.
Journal: Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
Published: July 08, 2025
Similar Doctors
Advanced in Progressive Familial Intrahepatic Cholestasis Type 3
Dr. Anurag Maheshwari
Hepatology
Advanced in Progressive Familial Intrahepatic Cholestasis Type 3
Dr. Anurag Maheshwari
Hepatology

St Paul Place Specialists Inc

301 Saint Paul St, 
Baltimore, MD 
 (1.2 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anurag Maheshwari is a Hepatologist in Baltimore, Maryland. Dr. Maheshwari is rated as a Distinguished provider by MediFind in the treatment of Progressive Familial Intrahepatic Cholestasis Type 3. His top areas of expertise are Hepatitis, Visceromegaly, Nonalcoholic Steatohepatitis (NASH), Endoscopy, and Colonoscopy.

Experienced in Progressive Familial Intrahepatic Cholestasis Type 3
Dr. Amol Rangnekar
Hepatology
Experienced in Progressive Familial Intrahepatic Cholestasis Type 3
Dr. Amol Rangnekar
Hepatology

Medstar Medical Group Ii LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (37.2 miles away)
703-558-1400
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amol Rangnekar is a Hepatologist in Washington, Washington, D.c.. Dr. Rangnekar is rated as a Distinguished provider by MediFind in the treatment of Progressive Familial Intrahepatic Cholestasis Type 3. His top areas of expertise are Hepatitis, Visceromegaly, Cirrhosis, Liver Transplant, and Endoscopy.

Experienced in Progressive Familial Intrahepatic Cholestasis Type 3
Dr. James Lewis
Hepatology
Experienced in Progressive Familial Intrahepatic Cholestasis Type 3
Dr. James Lewis
Hepatology

Medstar Medical Group Ii LLC

1145 19th St Nw, 311 Mmg At 19th Street Nw, 
Washington, DC 
 (36.3 miles away)
202-429-2401
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Lewis is a Hepatologist in Washington, Washington, D.c.. Dr. Lewis is rated as an Advanced provider by MediFind in the treatment of Progressive Familial Intrahepatic Cholestasis Type 3. His top areas of expertise are Hepatitis, Hepatitis C, Jaundice, Primary Biliary Cholangitis, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ravendhran's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile